![Amy Quinlan](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Amy Quinlan
Comptroller/Controller/Auditor bij
VOYAGER THERAPEUTICS, INC.
Vermogen: 126 784 $ op 31-08-2026
Profiel
Amy Quinlan is Chief Accounting Officer at Voyager Therapeutics, Inc. since 2026, with employment at the firm starting in 2025.
Formerly, Ms. Quinlan was Vice President-Finance at Vor Biopharma, Inc. from 2024 to 2025 and Vice President & Controller at Tetraphase Pharmaceuticals, Inc. from 2008 to 2020.
Education includes an undergraduate degree from Bryant University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 08-05-2026 | 36.749 ( 0,06% ) | 126 784 $ | 31-08-2026 |
Actieve functies van Amy Quinlan
| Bedrijven | Functie | Begin |
|---|---|---|
| VOYAGER THERAPEUTICS, INC. | Comptroller/Controller/Auditor | 08-05-2025 |
Eerdere bekende functies van Amy Quinlan
| Bedrijven | Functie | Einde |
|---|---|---|
| VOR BIOPHARMA INC. | Comptroller/Controller/Auditor | 30-09-2024 |
| TETRAPHASE PHARMACEUTICALS, INC. | Comptroller/Controller/Auditor | 01-08-2020 |
Opleiding van Amy Quinlan
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
55
Eerstegraads connecties
4
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
Tetraphase Pharmaceuticals, Inc.
 Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel antibiotics | Health Technology |
Bryant University
 Bryant University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Voyager Therapeutics, Inc.
 Voyager Therapeutics, Inc. BiotechnologyHealth Technology Develops gene therapies for fatal and debilitating diseases of the central nervous system | Health Technology |
Vor Biopharma, Inc.
 Vor Biopharma, Inc. BiotechnologyHealth Technology Engages in developing cell therapies | Health Technology |
